IL-17A as a potential therapeutic target for patients on peritoneal dialysis

View/ Open
Issue date
2020Author
Marchant, Vanessa
Tejera Muñoz, Antonio
Marquez Exposito, Laura
Rayego Mateos, Sandra
Rodrigues-Diez, Raul
Tejedor, Lucia
Santos Sanchez, Laura
Egido, Jesús
Fraser, Donald J.
López Cabrera, Manuel
Selgas, Rafael
Ruiz-Ortega, Marta
Suggested citation
Marchant, Vanessa;
Tejera Muñoz, Antonio;
Marquez Exposito, Laura;
Rayego Mateos, Sandra;
Rodrigues-Diez, Raul;
Tejedor, Lucia;
...
Ruiz-Ortega, Marta.
(2020)
.
IL-17A as a potential therapeutic target for patients on peritoneal dialysis.
Biomolecules, 2020, vol. 10, núm. 10, p.1-36.
https://doi.org/10.3390/biom10101361www.mdpi.com/journal/biomolecules.
Metadata
Show full item recordAbstract
Chronic kidney disease (CKD) is a health problem reaching epidemic proportions. There is no cure for CKD, and patients may progress to end-stage renal disease (ESRD). Peritoneal dialysis (PD) is a current replacement therapy option for ESRD patients until renal transplantation can be achieved. One important problem in long-term PD patients is peritoneal membrane failure. The mechanisms involved in peritoneal damage include activation of the inflammatory and immune responses, associated with submesothelial immune infiltrates, angiogenesis, loss of the mesothelial layer due to cell death and mesothelial to mesenchymal transition, and collagen accumulation in the submesothelial compact zone. These processes lead to fibrosis and loss of peritoneal membrane function. Peritoneal inflammation and membrane failure are strongly associated with additional problems in PD patients, mainly with a very high risk of cardiovascular disease. Among the inflammatory mediators involved in peritoneal damage, cytokine IL-17A has recently been proposed as a potential therapeutic target for chronic inflammatory diseases, including CKD. Although IL-17A is the hallmark cytokine of Th17 immune cells, many other cells can also produce or secrete IL-17A. In the peritoneum of PD patients, IL-17A-secreting cells comprise Th17 cells, gamma delta T cells, mast cells, and neutrophils. Experimental studies demonstrated that IL-17A blockade ameliorated peritoneal damage caused by exposure to PD fluids. This article provides a comprehensive review of recent advances on the role of IL-17A in peritoneal membrane injury during PD and other PD-associated complications.
Is part of
Biomolecules, 2020, vol. 10, núm. 10, p.1-36European research projects
The following license files are associated with this item: